Login
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc.

cytekbio.com

What Do They Do?

Sells cell-analysis instruments, reagents and support services to pharmaceutical and biotechnology companies, research institutions, contract research organizations and clinical laboratories.

How Do They Make Money?

Customers pay for instrument systems and accessories when they ship. Service contracts are billed upfront and cover service over the contract term; installation and repair services are billed as delivered.

revenue
SegmentShareRevenue
Product
Sold outright

72%
FY2022: 91%
Service
Mix

28%
FY2022: 9.4%

Who Are Their Customers?

Academic and government institutions, pharmaceutical and biotechnology companies, contract research organizations, and clinical laboratories buy through Cytek's direct sales teams in many regions; distributors and sales agents serve other markets.

Do Revenues Turn Into Profits?

No. It lost $66.5M in FY2025.

Operating income, FY2025
−20% of revenue
▼ −97% (Loss) vs FY2024 (−$20.5M, −10%)
Net income, FY2025
−33% of revenue
▼ −1005% (Loss) vs FY2024 (−$6M, −3%)
Free cash flow, FY2025
−4% of revenue
▼ Turned to a loss vs FY2024 ($21.9M, 11%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +2%
vs $52.3M in Q3 FY2025
Net income
▼ −11% (Loss)
vs −$5.5M in Q3 FY2025
Product share of revenue vs 72.9% in Q3 FY2025
  • Aug 24, 2026 Jury awards damages in patent case; Cytek plans to challenge the finding The jury awarded past damages of $20 million in lost profits and $36.11 million in royalties; Cytek intends post-verdict motions and may appeal.
  • Aug 5, 2026 Cytek raises its 2026 revenue outlook The updated full-year outlook is $207 million to $212 million, with the midpoint raised by $1 million.

Growing. Revenue grew 57% in 4 years, from $128M in FY2021 to $201.5M in FY2025, about 12% a year.

Paid digital licenses The latest report describes paid annual licenses and paid tiers for Cytek Cloud, a monetized digital ecosystem not described in the older report.

Broader instrument portfolio The latest report includes conventional flow and image-based instruments under the Amnis and Guava brands alongside the FSP portfolio; the older report's business description centers on FSP instruments.

Revenue over time
Product Service
$250M$125M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support